Does unified allergic airway disease impact on lung function and type 2 biomarkers?

Table 1 Characteristics of the study subjects and significant comparisons

	Allergic asthma with allergic rhinitis	Allergic asthma without allergic rhinitis
Age	55	49
F/M	17/13	11/19
SPT^†	2 (1–4)	2 (1–3)
ICS (µg)	750	580
LABA	70%	63%
LAMA	23%	10%
LTRA	43%	17%
THEO	3%	3%
OAH	53%	0
INS	100%	0
INAH	7%	0
ACQ-6	1.03 (0.13)	1.04 (0.17)
FEV₁ (% predicted)	84 (3)	92 (3)*
FEF_25–75 (% predicted)	43 (4)	59 (5)**
FeNO (ppb)	50 (6)	29 (4)**
Eos (cells/µL)	380 (34)	233 (36)**

ICS as beclomethasone equivalent dose
LABA long acting β2 agonist, LAMA long acting muscarinic antagonist, LTRA leukotriene receptor antagonist, THEO theophylline, OAH oral antihistamine, INS intranasal steroid, INAH intranasal antihistamine
Values are presented as mean (SEM), ^†median (IQR). *p < 0.05, **p < 0.01

ISSN: 1710-1492